Enlivex Therapeutics Ltd. (ENLV)

Market Cap	33.48M
Revenue (ttm)	n/a
Net Income (ttm)	-27.16M
Shares Out	18.60M
EPS (ttm)	-1.47
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	14,702
Open	1.78
Previous Close	1.84
Day's Range	1.78 - 1.86
52-Week Range	1.27 - 4.65
Beta	0.74
Analysts	Strong Buy
Price Target	12.00 (+566.67%)
Earnings Date	Dec 12, 2023

About ENLV

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company. It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors. The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors. En...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Dec 12, 1995
• Employees: 71
• Stock Exchange: NASDAQ
• Ticker Symbol: ENLV

Analyst Forecast

According to one analyst, the rating for ENLV stock is "Strong Buy" and the 12-month stock price forecast is $12.0.

Price Target

$12.0

(566.67% upside)

Analyst Consensus: Strong Buy